Up 21% since November, should I buy this dividend paying ASX All Ords healthcare share today?

A leading expert tips one ASX All Ords share to buy and one to sell today.

ASX All Ords healthcare share Monash IVF Group Ltd (ASX: MVF) has enjoyed a solid rebound since getting hammered in March and April 2025.

Trading for 72 cents a share in late afternoon trade on Monday, Monash IVF shares have gained more than 22% since market close on 19 November. For some context, the All Ordinaries Index (ASX: XAO) has gained 3.6% over this same time.

Atop that share price rebound, Monash IVF also paid out a 1.2 cent per share fully franked dividend to eligible stockholders on 10 April.

If we add that back in to Tuesday's share price, then the accumulated value of the stock is up 24.1% since 19 November.

Looking ahead, however, Bell Potter Securities' Christopher Watt forecasts a more difficult run over the coming months (courtesy of The Bull).

Five healthcare workers standing together and smiling.

Image source: Getty Images

Time to exit this ASX All Ords healthcare share?

"The fertility services company recently downgraded fiscal year 2026 guidance," Watt said. "It now expects underlying net profit after tax [NPAT] to range between $17 million and $18 million."

Monash IVF reported that adjustment, down from prior FY 2026 NPAT guidance of $20 million, on 12 June.

Management noted that the primary driver for the lowered FY 2026 earnings outlook was lower than expected Australian assisted reproductive technology (ART) market activity in the second half of the financial year.

Addressing the slowdown, Monash IVF CEO Victoria Atkinson said "Monash IVF has increased its Australian stimulated cycle market share during this period and has taken steps to reduce costs and improve operational performance."

But Bell Potter's Watt still foresees potential headwinds over the medium-term.

Summarising his sell recommendation on the ASX All Ords healthcare share, Watt said:

Across the Australian market, stimulated cycle volumes were down 4.7% on a rolling three-month basis to the end of April when compared to the prior corresponding period. Cost-of-living pressures and declining birth rates are structural headwinds for the whole industry.

New leadership has a genuine reset opportunity, but until there's evidence of an industry-wide recovery, I remain cautious.

Consider this surging ASX stock instead

Rather than buying ASX All Ords healthcare share Monash IVF, Watt recommended that investors consider buying ASX energy services provider GenusPlus Group (ASX: GNP)

"GNP appeals following the acquisition of MPC Kinetic Holdings, which broadens the business beyond electrical infrastructure and into gas, water and renewable energy services," he said.

Summarising his buy recommendation on GenusPlus shares, Watt concluded:

The deal adds scale, recurring customer relationships and complementary civil capability, while also improving the earnings outlook. With upgraded guidance, manageable leverage and exposure to major infrastructure investment, GenusPlus remains well placed to deliver growth from existing operations and future contract wins.

With a strong contracted position and the tailwind of tighter east-coast gas, I believe there's still upside to consensus.

As of late trade on Monday, GenusPlus shares are up 180% over the past 12 months.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended GenusPlus Group. The Motley Fool Australia has recommended GenusPlus Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »